Table 3.
Summarize of mean, standard difference, and sample size between treatment groups for included studies in a network meta-analysis.
| Study | Treatment | VAS | The number | Duration of | Frequency of | N | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Scores | of migraine days | migraine | migraine attacks | |||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
| Nie et al. (33), China | A+B | / | / | / | / | 11.11 | 4.03 | 2.79 | 0.9 | 45 |
| A | / | / | / | / | 9.44 | 3.6 | 2.21 | 0.8 | 45 | |
| C | / | / | / | / | 7.01 | 3.29 | 1.4 | 0.62 | 45 | |
| Zhao et al. (34), China | D | / | / | 4.4 | 3.1 | 36.3 | 10.9 | / | / | 18 |
| C | / | / | 2.1 | 2.5 | 14.2 | 9.9 | / | / | 18 | |
| Yu and Salmoni (35), Canada | A | / | / | 1.71 | 0.68 | 32.36 | 23.6 | / | / | 7 |
| E | / | / | 1.83 | 0.94 | 16.58 | 6.85 | / | / | 6 | |
| F | / | / | 0.4 | 1.02 | 5.3 | 11.44 | / | / | 5 | |
| Zhao et al. (36), China | G | 2.1 | 1.9 | 3.5 | 3.3 | / | / | 2.1 | 2.3 | 83 |
| F | 1.4 | 1.6 | 2.2 | 3.8 | / | / | 3.5 | 2.4 | 80 | |
| Li et al. (37), China | A+H | 4.95 | 0.89 | / | / | / | / | / | / | 32 |
| C | 3.64 | 0.93 | / | / | / | / | / | / | 32 | |
| Bicer et al. (38), Turkey | A | 3.35 | 1.76 | 4.54 | 2.11 | 17.09 | 15.41 | 3.24 | 1.57 | 29 |
| C | 4.24 | 2.22 | 5.08 | 1.73 | 14.68 | 11.66 | 4.4 | 1.93 | 25 | |
| Wang et al. (39), Australia | A | 1.6 | 1.6 | 6.6 | 5.4 | 3 | 3.4 | / | / | 26 |
| F | 0.8 | 1.9 | 2.3 | 6.7 | 0.9 | 4.6 | / | / | 24 | |
| Zhao et al. (40), China | A | 2.096 | 0.25 | 6.34 | 6.99 | / | / | 3.98 | 3.64 | 40 |
| F | 1.11 | 0.25 | 5.82 | 6.67 | / | / | 2.88 | 3.22 | 40 | |
| Li et al. (41), China | A | 1 | 3.7 | / | / | / | / | / | / | 56 |
| F | 0.5 | 1.8 | / | / | / | / | / | / | 56 | |
| Diener et al. (42), Germany | A | / | / | 2.3 | 3.6 | / | / | / | / | 313 |
| F | / | / | 1.5 | 3.8 | / | / | / | / | 339 | |
| C | / | / | 2.1 | 4 | / | / | / | / | 308 | |
| Musil et al. (43), Czech Republic | A | 0.18 | 1.3 | 5.5 | 11.2 | 0.46 | 5.64 | / | / | 42 |
| C | −0.3 | 0.76 | 2 | 4.9 | 0.07 | 4.5 | / | / | 44 | |
| Farahmand et al. (44), Iran | I | 7.1 | 1.3 | / | / | / | / | / | / | 30 |
| F | 6.4 | 1.9 | / | / | / | / | / | / | 30 | |
| Xu and Mi (45), China | E+C | / | / | / | / | / | / | 2 | 1.2 | 49 |
| C | / | / | / | / | / | / | 1.9 | 1.1 | 49 | |
| Wang et al. (46), China | A | 2.86 | 1.32 | / | / | 11.92 | 14.01 | 1.54 | 0.91 | 19 |
| F | 0.62 | 1.45 | / | / | 3.81 | 16.26 | 0.05 | 1.07 | 19 | |
| Safonov and Naprienko (47), Russia | A | / | / | 14.54 | 1.73 | / | / | / | / | 22 |
| G | / | / | 14.45 | 1.74 | / | / | / | / | 20 | |
| F | / | / | 6.4 | 1.44 | / | / | / | / | 20 | |
| Li et al. (48), China | A | 2.08 | 1.35 | / | / | / | / | 1.83 | 2.7 | 12 |
| F | 1.27 | 1.48 | / | / | / | / | −0.15 | 3.37 | 13 | |
| Li et al. (49), China | A | 2.54 | 1.22 | / | / | / | / | 1.46 | 3.26 | 13 |
| F | 1.14 | 1.44 | / | / | / | / | 0 | 3.45 | 11 | |
| Feng (50), China | J | 5.95 | 0.38 | / | / | / | / | / | / | 30 |
| G | 4.67 | 0.36 | / | / | / | / | / | / | 30 | |
| Wang et al. (51), China | K | 5.3 | 1.5 | / | / | 40.4 | 7.9 | 7.8 | 1.9 | 32 |
| C | 2.9 | 1.6 | / | / | 36 | 6.8 | 5.8 | 1.6 | 32 | |
| Hou et al. (52), China | K | 5 | 1.3 | / | / | 6.3 | 2.3 | 5.7 | 1.8 | 42 |
| F | 0.5 | 2 | / | / | 0.2 | 2.1 | 0.1 | 2.4 | 19 | |
| Foroughipour et al. (53), Iran | A | / | / | / | / | / | / | 1.7 | 1.1 | 50 |
| F | / | / | / | / | / | / | 0.7 | 0.9 | 50 | |
| Wang et al. (54), China | A | 2.4 | 2.1 | / | / | / | / | / | / | 75 |
| F | 0.7 | 2 | / | / | / | / | / | / | 75 | |
| Wallasch et al. (55), Germany | A | / | / | 3.73 | 3 | 39.9 | 38.4 | / | / | 18 |
| F | / | / | 1.23 | 2.55 | 15.6 | 37 | / | / | 17 | |
| Ferro et al. (56), Brazil | A+L | 6.4 | 3.1 | / | / | / | / | / | / | 22 |
| A | 5.6 | 2.4 | / | / | / | / | / | / | 22 | |
| L | 3.7 | 2.1 | / | / | / | / | / | / | 23 | |
| Ceccherelli et al. (57), Padova | A | 2.78 | 1.54 | / | / | / | / | / | / | 18 |
| I | 2.06 | 1.87 | / | / | / | / | / | / | 17 | |
| Yang et al. (58), Taiwan | A | / | / | 10.5 | 2.8 | / | / | / | / | 33 |
| C | / | / | 7.8 | 3.6 | / | / | / | / | 33 | |
| Zhong et al. (59), China | G | / | / | / | / | 3.91 | 1.16 | 2.4 | 0.4 | 114 |
| C | / | / | / | / | 3.17 | 1.29 | 1.8 | 0.5 | 104 | |
| Zhou et al. (60), China | G | 1.4 | 1.1 | / | / | / | / | / | / | 146 |
| C | 0.5 | 1 | / | / | / | / | / | / | 140 | |
| Linde et al. (61), Germany | A | / | / | 2.2 | 2.7 | / | / | 1.5 | 1.2 | 145 |
| F | / | / | 2.2 | 2.7 | / | / | 1.6 | 1.3 | 81 | |
| Streng et al. (62), Germany | A | / | / | 2.6 | 2.7 | / | / | 1.4 | 1.4 | 59 |
| C | / | / | 1.9 | 3 | / | / | 1 | 1.4 | 55 | |
| Linde et al. (63), Germany | A | / | / | 3 | 2.6 | / | / | 1.3 | 1.2 | 145 |
| F | / | / | 2.8 | 2.5 | / | / | 1.2 | 1.2 | 81 | |
| Allais et al. (64), Italy | I | 3 | 0.25 | / | / | / | / | / | / | 46 |
| F | 0.7 | 0.23 | / | / | / | / | / | / | 48 | |
| Lavies (65), Britain | M | / | / | −4 | 3.3 | / | / | / | / | 6 |
| F | / | / | −2 | 6.2 | / | / | / | / | 6 | |
| Xu et al. (66), China | A | 2.2 | 2.5 | 3.9 | 3 | / | / | 2.3 | 1.7 | 58 |
| F | 0.9 | 1.9 | 2.2 | 3.2 | / | / | 1.6 | 2.5 | 60 | |
| Zhang et al. (67), China | A | 3.54 | 2.03 | / | / | / | / | / | / | 69 |
| C | 2.92 | 1.79 | / | / | / | / | / | / | 64 | |
| Meng et al. (68), China | A | 2.62 | 3.07 | / | / | 1.99 | 1.12 | 2.61 | 1.17 | 30 |
| F | 2 | 2.56 | / | / | 0.64 | 1.31 | 0.6 | 1.42 | 30 | |
| Xu and Wang (69), China | A | 1.37 | 0.29 | / | / | / | / | / | / | 30 |
| F | 0.47 | 0.28 | / | / | / | / | / | / | 30 | |
| Yang et al. (70), China | A | 3.5 | 1.45 | 2.65 | 1.98 | / | / | 2.4 | 1.82 | 20 |
| C | 1.79 | 1.28 | 1.52 | 1.97 | / | / | 1.42 | 1.99 | 19 | |
| Song et al. (71), China | A+H | 5.47 | 1.63 | / | / | / | / | / | / | 45 |
| C | 3.75 | 1.66 | / | / | / | / | / | / | 45 | |
A, conventional acupuncture; B, massage; C, analgesic; D, embedding needle therapy; E, acupressure; F, placebo; G, electroacupuncture; H, cupping; I, auricular acupuncture; J, acupoint implantation; K, acupoint injection; L, traditional Chinese medicine; M, laser acupuncture.